NCT06619808 Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases
| NCT ID | NCT06619808 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jinling Hospital, China |
| Condition | Metabolic Dysfunction-associated Steatotic Liver Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-07-29 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2024-07-29 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) works to treat Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD). The main questions it aims to answer are: Does HBOT decreases the fat content and fibrosis state of liver in adult MASLD patients? Does HBOT improves the liver function and metabolic condition in adult MASLD patients? Participants will: Receive HBOT for 20 times in 1 month or recerive regular drug; Visit the clinic for checkups and tests at the starting, ending of the therapy and 6 month after the therapy.
Eligibility Criteria
Inclusion Criteria: * Metabolic dysfunction-associated steatotic liver disease patients Exclusion Criteria: * Participants are unfit for hyperbaric treatment. * Participants with prior oxygen therapy within the last 6 months. * Participants with history of viral hepatitis, hemochromatosis, Wilson disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, biliary obstruction, alpha-1 antitrypsin deficiency. * Participants with severe organ dysfunctions or malignant tumors. * Participants have weight loss plan or major operations within the last 6 months. * Participants are unable to provide informed consent or currently participating in or has within the last 3 months participated in any other clinical trial. * Participants are pregnant or lactating. * Participants with claustrophobia or that cannot decompress properly.
Contact & Investigator
Miaofang Yang, MD
STUDY DIRECTOR
General Hospital of Eastern Theater Command, China
Frequently Asked Questions
Who can join the NCT06619808 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Metabolic Dysfunction-associated Steatotic Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06619808 currently recruiting?
Yes, NCT06619808 is actively recruiting participants. Contact the research team at 522023350160@smail.nju.edu.cn for enrollment information.
Where is the NCT06619808 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06619808 clinical trial?
NCT06619808 is sponsored by Jinling Hospital, China. The principal investigator is Miaofang Yang, MD at General Hospital of Eastern Theater Command, China. The trial plans to enroll 150 participants.